Castle Biosciences' Q3 revenue beats estimates

Castle Biosciences

03/11/2025 21:24

Overview

Castle Biosciences Q3 2025 revenue of $83 mln beats analyst expectations

Company reports Q3 2025 net loss of $0.5 mln, down from net income in Q3 2024

Outlook

Castle Biosciences raises full-year 2025 revenue guidance to $327-335 mln

Company launches AdvanceAD-Tx test for atopic dermatitis treatment decisions

Result Drivers

CORE TESTS GROWTH - DecisionDx-Melanoma and TissueCypher test reports increased significantly, driving revenue growth

COVERAGE IMPACT - Novitas LCD and discontinuation of IDgenetix affected revenue and test report volumes

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$83.04 mln
$71.20 mln (8 Analysts)
Q3 Net Income
-$501,000
Q3 Operating Expenses
$89.84 mln
Q3 Operating Income
-$6.80 mln
Q3 Pretax Profit
-$386,000


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Castle Biosciences Inc is $35.50, about 28.2% above its October 31 closing price of $25.50

Press Release: ID:nGNX3VMPgT

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)